Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 3;8(1):418.
doi: 10.1038/s41392-023-01642-x.

Smart nanoparticles for cancer therapy

Affiliations
Review

Smart nanoparticles for cancer therapy

Leming Sun et al. Signal Transduct Target Ther. .

Abstract

Smart nanoparticles, which can respond to biological cues or be guided by them, are emerging as a promising drug delivery platform for precise cancer treatment. The field of oncology, nanotechnology, and biomedicine has witnessed rapid progress, leading to innovative developments in smart nanoparticles for safer and more effective cancer therapy. In this review, we will highlight recent advancements in smart nanoparticles, including polymeric nanoparticles, dendrimers, micelles, liposomes, protein nanoparticles, cell membrane nanoparticles, mesoporous silica nanoparticles, gold nanoparticles, iron oxide nanoparticles, quantum dots, carbon nanotubes, black phosphorus, MOF nanoparticles, and others. We will focus on their classification, structures, synthesis, and intelligent features. These smart nanoparticles possess the ability to respond to various external and internal stimuli, such as enzymes, pH, temperature, optics, and magnetism, making them intelligent systems. Additionally, this review will explore the latest studies on tumor targeting by functionalizing the surfaces of smart nanoparticles with tumor-specific ligands like antibodies, peptides, transferrin, and folic acid. We will also summarize different types of drug delivery options, including small molecules, peptides, proteins, nucleic acids, and even living cells, for their potential use in cancer therapy. While the potential of smart nanoparticles is promising, we will also acknowledge the challenges and clinical prospects associated with their use. Finally, we will propose a blueprint that involves the use of artificial intelligence-powered nanoparticles in cancer treatment applications. By harnessing the potential of smart nanoparticles, this review aims to usher in a new era of precise and personalized cancer therapy, providing patients with individualized treatment options.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests. L.C. is an editorial board member of the Signal Transmission and Targeted Therapy.

Figures

Fig. 1
Fig. 1
Schematic illustration of smart nanoparticles for cancer treatment
Fig. 2
Fig. 2
Nanocarriers for smart nanoparticles
Fig. 3
Fig. 3
The endogenous and exogenous stimuli of smart nanoparticles for cancer therapy
Fig. 4
Fig. 4
Tumor-specific target modification of smart nanoparticles categorized by aptamer, antibody, peptide, folic acid and transferrin
Fig. 5
Fig. 5
Timeline of the development of smart nanoparticles for cancer diagnosis and treatment

References

    1. Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 2021;71:209–249. - PubMed
    1. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 2018;68:394–424. - PubMed
    1. Messinger YH, et al. Bortezomib combined with VXLD chemotherapy is highly effective in advanced B-lineage acute lymphoblastic leukemia allowing early study termination due to efficacy. A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Phase II Study. Blood. 2011;118:251. doi: 10.1182/blood.V118.21.251.251. - DOI
    1. Hosomi Y, et al. Gefitinib alone versus gefitinib plus chemotherapy for non–small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 Study. J. Clin. Oncol. 2020;38:115–123. doi: 10.1200/JCO.19.01488. - DOI - PubMed
    1. Baghban R, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 2020;18:59. doi: 10.1186/s12964-020-0530-4. - DOI - PMC - PubMed